Pharmacologic aspects of new antiretroviral drugs

Product Categories

Therapeutic Areas

Targets

Antiinfectives

Endocrine and Metabolic Agents

Products with DMF


	Sign up for our mailing lists to receive more information in the future. Email Address: Compounds Biologics Research Formulations Nanomaterials Alternative Energy Radiolabeled Unsubscribe

ACC Expands products offerings. Check out our new section on Alternative Energy

READ NEWS

Blog - Pharmacologic aspects of new antiretroviral drugs

Last Updated February 6, 2009

The biggest challenge facing highly antiretroviral-experienced patients and their caregivers is the diminishing number of therapeutic options available that sustain activity despite increasing numbers of drug-resistance mutations. New options in antiretroviral treatment have been introduced: two new members of traditional antiretroviral classes (darunavir and etravirine) and two drugs with novel mechanisms of action (raltegravir and maraviroc). Each was approved for use in treatment-experienced patients. A fifth drug-containing efavirenz, tenofovir, and emtricitabine (Atripla; Bristol-Myers Squibb, New York, NY, and Gilead Sciences, Foster City, CA)-is a novel coformulation of existing drugs from two different classes, simplifying administration with the intent of increasing adherence. Because successful management of HIV infection requires the simultaneous use of three or more drugs, understanding the pharmacologic aspects of coadministration is critical. This review summarizes the pharmacokinetic properties affecting the administration of these recently approved drugs in light of highly active antiretroviral treatment guidelines.

Posted by Long MC, King JR, Acosta EP on February 6, 2009

Comments 0 of 0

If you would like to comment on this post, please fill out the form below.

* denotes required field

Post Your Comments On*

Email Address*

Name*

Comment*

99999 characters remaining

Enter the code shown:

*All comments will undergo a review process before they are posted online. This is to prevent spam and ads from being posted. Thank you for your time and patience.

Opinions expressed on the ACC Corporation Blog and all corresponding comments are the individual opinions of the original authors and don’t in any way reflect the opinions of ACC Corporation.

Return to Posts